|
Sensitivity analyses |
||||||
| Univariate odds ratio (95% CI) |
Predictive accuracy (AUC) |
|||||
|
|
||||||
| Definition of advanced cancer |
Number of cases/controls |
Total PSA (ng/ml) |
Free to total PSA (%) |
Total PSA (ng/ml) |
Free to total PSA (%) |
Multivariable model |
|
|
||||||
| Metastases or ≥ T3 |
161/436 |
4.29 (2.98, 6.18) |
0.92 (0.89, 0.95) |
0.791 |
0.641 |
0.785 |
| Less inclusive* |
62/163 |
3.02 (1.87, 4.90) |
0.90 (0.84, 0.95) |
0.762 |
0.674 |
0.751 |
| More inclusive† |
190/512 |
4.05 (2.89, 5.67) |
0.92 (0.89, 0.95) |
0.782 |
0.645 |
0.780 |
|
* Presence of skeletal metastases at time of diagnosis. † Presence of any of the following criteria at time of diagnosis: skeletal metastasis, clinical stage at least T3, positive lymph node, WHO grade III. | ||||||
Ulmert et al. BMC Medicine 2008 6:6 doi:10.1186/1741-7015-6-6 |
||||||